1<!DOCTYPE html><html lang="en"><head><meta charSet="utf-8" data-next-head=""/><meta name="viewport" content="width=device-width, initial-scale=1" data-next-head=""/><link rel="icon" href="/images/favicon.ico" data-next-head=""/><title data-next-head="">About CTCL</title><meta name="robots" content="index,follow" data-next-head=""/><meta property="og:title" content="About CTCL" data-next-head=""/><meta property="og:url" content="https://www.lymphirhcp.com/about-ctcl" data-next-head=""/><meta property="og:type" content="website" data-next-head=""/><link rel="canonical" href="https://www.lymphirhcp.com/about-ctcl" data-next-head=""/><link rel="preload" href="/images/desktop-logo-247x50.svg" as="image" data-next-head=""/><link rel="preconnect" href="https://fonts.googleapis.com"/><link rel="preconnect" href="https://fonts.gstatic.com" crossorigin="true"/><link href="https://fonts.googleapis.com/css2?family=Nunito+Sans:ital,wght@0,400;0,700;0,800;1,400;1,700;1,800&family=Montserrat:ital,wght@0,100..900;1,100..900&family=Poppins:ital,wght@0,400;0,700;1,400;1,700&display=swap" rel="stylesheet"/><link rel="preload" href="/_next/static/chunks/38b7b4816bd2434a.css" as="style"/><link rel="stylesheet" href="/_next/static/chunks/38b7b4816bd2434a.css" data-n-g=""/><link rel="preload" href="/_next/static/chunks/6375e6b79b28253a.css" as="style"/><link rel="stylesheet" href="/_next/static/chunks/6375e6b79b28253a.css" data-n-g=""/><noscript data-n-css=""></noscript>
1<script src="/_next/static/chunks/97c7e432c3173e0b.js" defer=""></script>
1<script src="/_next/static/chunks/adde44cadcceeb00.js" defer=""></script>
1<script src="/_next/static/chunks/d94cb5a0396fae63.js" defer=""></script>
1<script src="/_next/static/chunks/94bf6067c5b34713.js" defer=""></script>
1<script src="/_next/static/chunks/turbopack-1b4d16b615be62bb.js" defer=""></script>
1<script src="/_next/static/chunks/2b38932129406e4e.js" defer=""></script>
1<script src="/_next/static/chunks/93cccff5570e7b2f.js" defer=""></script>
1<script src="/_next/static/chunks/turbopack-7bb6bc34d4753533.js" defer=""></script>
1<script src="/_next/static/e2ec-LxESpgki9ZsMI16Z/_ssgManifest.js" defer=""></script>
1<script src="/_next/static/e2ec-LxESpgki9ZsMI16Z/_buildManifest.js" defer=""></script>
1<style id="__jsx-2637089790">div.jsx-2637089790{height:20px}@media screen and (width>=768px){div.jsx-2637089790{height:45px}}</style><style id="__jsx-2970251956">div.jsx-2970251956{null}div.jsx-2970251956 :is(h1,h2,h3,h4,h5,h6){null}</style><style id="__jsx-896410394">div.jsx-896410394{height:45px}@media screen and (width>=768px){div.jsx-896410394{height:60px}}</style><style id="__jsx-3562595134">div.jsx-3562595134{height:50px}@media screen and (width>=768px){div.jsx-3562595134{height:60px}}</style></head><body>
vendor: 67 bytes, line 1
1<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=
1GTM-WKFBBNVG
vendor: 82 bytes, line 1
1" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
1<div id="__next"><div class="theme-root" data-theme="light-bg"><div data-theme="light-bg"></div><aside><div class="container"><a href="#main" class="skip-to-main-content">Skip to main content</a></div></aside><header><nav class=" navbar navbar-expand-lg navbar-light"><button aria-controls="navbar-nav" type="button" aria-label="Toggle navigation" class="navbar-toggler collapsed"><span class="icon-bar"></span><span class="icon-bar"></span><span class="icon-bar"></span></button><div class="justify-content-end navbar-collapse collapse" id="navbar-nav"><div class="nav-wrapper"><div class="utility-nav " data-theme="light-bg"><div class="container"><div class="navbar-nav"><p></p><div class="links"><div class="nav-item"><a target="_blank" class="nav-link " href="/pdf/prescribing-information.pdf"><span>Prescribing Information</span></a></div><div class="nav-item"><a target="_self" class="nav-link " href="/resources/request-a-rep/"><span>Request a Rep</span></a></div></div></div></div></div><div class="d-block site-nav" data-theme="light-bg"><div class="navbar-nav"><a href="/"><span class="navbar-brand"><img alt="LYMPHIR logo." width="247" height="50" decoding="async" data-nimg="1" style="color:transparent" src="/images/desktop-logo-247x50.svg"/></span></a><div class="nav-item"><a target="_self" class="nav-link active " href="/about-ctcl/"><span>About CTCL</span></a></div><div class="nav-item"><div class="show dropdown nav-item"><div class="dropdown-toggle"><span class="nav-link d-inline-block " aria-haspopup="true" aria-expanded="false" id="nav-lymphir-moa"><span>LYMPHIR MOA</span></span></div><div class="dropdown-menu d-inline-block d-none" aria-labelledby="nav-lymphir-moa"><div class="nav-item"><a target="_self" class="nav-link " href="/lymphir-moa/the-il-2-receptor/"><span>The IL-2 receptor</span></a></div><div class="nav-item"><a target="_self" class="nav-link " href="/lymphir-moa/how-lymphir-works/"><span>How LYMPHIR works</span></a></div></div></div></div><div class="nav-item"><a target="_self" class="nav-link " href="/efficacy/"><span>Efficacy</span></a></div><div class="nav-item"><a target="_self" class="nav-link " href="/safety/"><span>Safety</span></a></div><div class="nav-item"><a target="_self" class="nav-link " href="/dosing/"><span>Dosing</span></a></div><div class="nav-item"><div class="show dropdown nav-item"><div class="dropdown-toggle"><span class="nav-link d-inline-block " aria-haspopup="true" aria-expanded="false" id="nav-resources"><span>Resources</span></span></div><div class="dropdown-menu d-inline-block d-none" aria-labelledby="nav-resources"><div class="nav-item"><a target="_self" class="nav-link " href="/resources/patient-support/"><span>Patient support</span></a></div><div class="nav-item"><a target="_self" class="nav-link " href="/resources/hcp-resources/"><span>HCP resources</span></a></div></div></div></div></div></div></div></div></nav></header><section class="banner"><div class="container"><div class="row"><div class="col-12"><div class="content"><p><strong>LYMPHIR is available for use.</strong></p></div></div></div></div></section>
1<main data-pagefind-body="true" id="main" class="null"><section class="" data-cms-bind="#content_blocks"><div class=" content-block" data-cms-bind="#content_blocks[0]"><section class="hero "><div class="container"><div class="row"><div class="col-12 col-md-10 me-md-auto"><div class="hero-content has-breadcrumb"><div class="breadcrumbs" data-pagefind-ignore="true"><span class="breadcrumbs__item"><a href="/"><span>Home</span></a><svg xmlns="http://www.w3.org/2000/svg" width="12" height="19"><path d="M0.11502 0L4.52133 9.54441L0 19L11.6923 9.48592L0.11502 0Z"></path></svg></span><span class="breadcrumbs__item"><span><span>About CTCL</span></span></span></div><div><h1><span class="accent-color"><strong>CTCL IS AN INCURABLE COMPLEX CANCER</strong></span><strong> WITH NO SINGLE DEFINITIVE TREATMENT PATHWAY</strong></h1></div></div></div></div></div></section></div><div class=" content-block" data-cms-bind="#content_blocks[1]"><section class="factoid clipped"><div class="container"><div class="row flex-md-row-reverse align-content-md-start"><div class="col-10 offset-2 col-md-11"><div class="factoid-banner false shorter"><img src="/images/flag-end-left.svg" class="flag-end" alt=""/><div class="factoid-banner-content"><p>There is no universally defined treatment pathway for CTCL. Patients with advanced or refractory disease have limited durable and tolerable options, and many aspects of treatment need to be considered when choosing a course of therapy<sup>1,2</sup></p></div></div></div><div class="col-12 col-md-7 col-xl-8"></div></div></div></section></div><div class=" content-block" data-cms-bind="#content_blocks[2]"><section data-theme="light-bg"><div class="container-content-block container "><div class="jsx-2637089790 "></div><div data-cms-bind="#content_blocks[2].content_blocks[1]" class="jsx-2970251956 "><h2>Advanced disease and pruritus can heavily impact quality of life in patients</h2><ul><li><p>Pruritus is a common and troublesome symptom in CTCL<sup>3</sup></p></li><li><p>Itching can be very hard to manage in patients with CTCL. A worsening of pruritus is often associated with disease progression. The pathogenesis has not yet been fully elucidated<sup>4</sup></p></li><li><p>Symptoms of pruritus can be present in a large majority (nearly 90%) of patients with CTCL, and may be associated with decreased quality of life for patients. Patients should be evaluated for pruritus at each visit<sup>1</sup></p></li><li><p>Quality of life worsens for patients with CTCL as the disease advances. Patients may experience itching and pain, as well as poor sleep, depression, and anxiety<sup>5</sup></p></li></ul></div><div class="jsx-896410394 "></div></div></section></div><div class=" content-block" data-cms-bind="#content_blocks[3]"><section class="references no-line"><div class="container"><div class="row"><div class="col-12 ref-col"><p><strong>References:</strong><span><strong> <!-- -->1<!-- -->. </strong><span>Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>) for primary cutaneous lymphomas V.3.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed November 13, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.</span></span><span><strong> <!-- -->2<!-- -->. </strong><span>Shimshak S, Sokumbi O, Isaq N, Goyal A, Comfere N. A practical guide to the diagnosis, evaluation, and treatment of cutaneous T-Cell lymphoma. <em>Dermatol Clin</em>. 2023;41(1):209-229. doi:10.1016/j.det.2022.07.019</span></span><span><strong> <!-- -->3<!-- -->. </strong><span>Wright A, Wijeratne A, Hung T, et al. Prevalence and severity of pruritus and quality of life in patients with cutaneous T-cell lymphoma. <em>J Pain Symptom Manage.</em> 2013;45(1):114-119. doi:10.1016/j.jpainsymman.2012.01.012</span></span><span><strong> <!-- -->4<!-- -->. </strong><span>
1Serrano L, Martinez-Escala ME, Zhou XA, Guitart J. Pruritus in Cutaneous T-Cell Lymphoma and Its Management. <em>Dermatol Clin.</em> 2018;36:245â58. doi:10.1016/j.det.2018.02.011</span></span><span><strong> <!-- -->5<!-- -->. </strong><span>Scarisbrick JJ, Bagot M, Ortiz-Romero PL. The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T-cell lymphoma. <em>Br J Haematol.</em> 2021;192(4):683-696. doi:10.1111/bjh.17117</span></span></p></div></div></div></section></div><div class=" content-block" data-cms-bind="#content_blocks[4]"><div class="jsx-3562595134 "></div></div><div class=" content-block" data-cms-bind="#content_blocks[5]"><section class="next-section "><div class="container"><div class="heading">NEXT: Learn more about LYMPHIR<img src="/images/flag-end-right.svg" class="flag-end" alt=""/></div><div class="row"><div class="col-12"><div class="next-links"><div class="next-link"><a class="btn btn-tertiary " target="_self" href="/lymphir-moa/how-lymphir-works/"><span class="text">View mechanism of action</span><span class="icon-right ChevronRight"><svg xmlns="http://www.w3.org/2000/svg" width="12" height="19"><path d="M0.11502 0L4.52133 9.54441L0 19L11.6923 9.48592L0.11502 0Z"></path></svg></span></a></div><div class="next-link"><a class="btn btn-tertiary " target="_self" href="/efficacy/"><span class="text">View phase III trial results</span><span class="icon-right ChevronRight"><svg xmlns="http://www.w3.org/2000/svg" width="12" height="19"><path d="M0.11502 0L4.52133 9.54441L0 19L11.6923 9.48592L0.11502 0Z"></path></svg></span></a></div><div class="next-link"><a class="btn btn-tertiary " target="_self" href="/safety/"><span class="text">See safety information</span><span class="icon-right ChevronRight"><svg xmlns="http://www.w3.org/2000/svg" width="12" height="19"><path d="M0.11502 0L4.52133 9.54441L0 19L11.6923 9.48592L0.11502 0Z"></path></svg></span></a></div></div></div></div></div></section></div></section></main><aside class="isi-container "><div id="isi"><div class="container"><section class="isi-heading-row"><div class="row"><div class="col-12"><p class="isi-heading">IMPORTANT SAFETY INFORMATION</p></div><button role="button" id="expand-ISI-toggle" aria-label="Expand ISI"><span class="expanded">â</span><span class="collapsed">+</span></button></div></section><section class="isi-content-row"><div class="row"><div class="col-12"><div class="black-box"><p class="isi-big-heading">WARNING: CAPILLARY LEAK SYNDROME</p><p>Capillary leak syndrome (CLS), including life-threatening or fatal reactions, can occur in patients receiving LYMPHIR. Monitor patients for signs and symptoms of CLS during treatment. Withhold LYMPHIR until CLS resolves, or permanently discontinue based on severity.</p></div><div class="content-title"><p>Warnings and Precautions</p></div><div><p class="isi-heading">Capillary Leak Syndrome</p><p>LYMPHIR can cause capillary leak syndrome (CLS), including life-threatening or fatal reactions. CLS was defined in the clinical trials as the occurrence of at least 2 of the following symptoms at any time during LYMPHIR therapy: hypotension, edema, and serum albumin <span class="no-wrap"><3 g/dL</span>. These symptoms were not required to occur simultaneously to be characterized as CLS.</p><p>As defined, CLS occurred in 27% of patients in the pooled population across 3 clinical trials, including 8% with Grade 3. There was one (0.8%) fatal occurrence of CLS. Of the patients with CLS, 22% had recurrence. The majority of CLS events (81%) occurred within the first <span class="no-wrap">2 cycles</span> of treatment. The median time to onset from Cycle 1, Day 1 was 6.5 days (range: 1 to 77), the median duration of CLS was 14 days (range: 2 to 40), and 75% of patients had resolution.</p><p>Regularly assess patients for weight gain, new onset or worsening of edema, dyspnea, and hypotension (including orthostatic changes). Monitor serum albumin levels prior to the initiation of each cycle of therapy and more often as clinically indicated.</p><p>Withhold, reduce dose, or permanently discontinue based on severity. If LYMPHIR is withheld, resume LYMPHIR following resolution of CLS and when serum albumin is â¥3 g/dL.</p><p class="isi-heading">Visual Impairment</p><p>LYMPHIR can cause serious visual impairment, including changes in visual acuity and color vision. In the pooled population across <span class="no-wrap">3 clinical</span> trials, visual impairment occurred in 9%, with Grade 1 in 8% and Grade 2 in 1%. The most commonly reported symptom was blurred vision. Of the patients with visual impairment, 67% had resolution of their visual impairment.</p><p>Perform baseline ophthalmic examination and monitor as clinically indicated. If patients experience symptoms of visual impairment, such as changes in visual acuity, changes in color vision, or blurred vision, refer for ophthalmologic evaluation. Withhold LYMPHIR until visual impairment resolves or permanently discontinue based on severity.</p><p class="isi-heading">Infusion-Related Reactions</p><p>LYMPHIR can cause serious infusion-related reactions. Infusion-related reactions were reported in 69% of patients in the pooled population across 3 clinical trials of patients who received LYMPHIR, with Grade 3 infusion-related reactions in 3.4%. Eighty-three percent of infusion-related reactions occurred in Cycles 1 and 2. The most common symptoms included nausea, fatigue, chills, musculoskeletal pain, vomiting, fever, and arthralgia.</p><p>Premedicate patients for the first 3 cycles prior to starting a LYMPHIR infusion. Monitor patients frequently during infusion. For Grade 2 or higher infusion reactions, premedicate at least <span class="no-wrap">30 minutes</span> prior to each subsequent infusion with a systemic steroid for at least 3 cycles. Interrupt or discontinue LYMPHIR based on severity. Institute appropriate medical management.</p><p class="isi-heading">Hepatotoxicity</p><p>LYMPHIR can cause hepatotoxicity. In the pooled safety population, elevated ALT occurred in 70% of patients, with Grade 3 ALT occurring in 22%; elevated AST occurred in 64% of patients, with Grade 3 AST elevation occurring in 9%. For Grade 3 events, median time to onset was <span class="no-wrap">8 days</span> (range: 1 to 15 days); median time to resolution was 15 days (range: 7 to 50 days); all cases of Grade 3 ALT or AST elevations resolved. Elevated total bilirubin occurred in 5% of patients, with Grade 3 occurring in 0.9%.</p><p>Monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated. Withhold, reduce dose, or permanently discontinue LYMPHIR based on severity.</p><p class="isi-heading">Embryo-Fetal Toxicity</p><p>Based on its mechanism of action, LYMPHIR can cause fetal harm when administered to a pregnant woman. Verify the pregnancy status of females of reproductive potential prior to the initiation of LYMPHIR. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment and for 7 days following the last dose of LYMPHIR.</p><p class="isi-big-heading">Adverse Reactions</p><p>In the pooled safety population, the most common (â¥20%) adverse reactions, including laboratory abnormalities, were increased transaminases (70%), albumin decreased (53%), nausea (40%), edema (35%), hemoglobin decreased (34%), fatigue (30%), musculoskeletal pain (26%), rash (23%), chills (22%), constipation (22%), pyrexia (21%), and CLS (20%).</p><p class="isi-big-heading">Use in Specific Populations</p><p><strong>Lactation: </strong>Advise women not to breastfeed during treatment with LYMPHIR and for 7 days after the last dose.</p><p><strong>You may report side effects to the FDA at <a href='tel:1-800-332-1088' class='phone-link'>1-800-FDA-1088</a> or </strong><a href="https://www.fda.gov/medwatch" target="_blank" rel="noopener"><strong>www.fda.gov/medwatch</strong></a><strong>. You may also report side effects to Citius Oncology at <a href='tel:1-844-459-6744' class='phone-link'>1-844-459-6744</a>.</strong></p><p class="isi-big-heading">INDICATIONS AND USAGE</p><p>LYMPHIR (denileukin diftitox-cxdl) is indicated for the treatment of adult patients with relapsed or refractory
1Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.</p><p><strong>Please see full </strong><a href="/pdf/prescribing-information.pdf" target="_blank" rel="noopener"><strong>Prescribing Information</strong></a><strong> for additional Important Safety Information, including Boxed Warning.</strong></p></div></div></div></section></div></div></aside><footer class="page-footer"><div class="container"><div class="row"><div class="col-12"><div id="site-footer"><div class="upper"><div class="left"><ul class="footer-links"><li><a target="_blank" class="" href="https://citiuspharma.com/terms-of-use/default.aspx"><span>Terms of Use</span></a></li><li><a target="_blank" class="" href="https://citiuspharma.com/privacy-policy/default.aspx"><span>Privacy Policy</span></a></li><li><a target="_self" class="" href="/sitemap/"><span>Site Map</span></a></li></ul><a class="brand-logo" target="_blank" href="https://www.citiuspharma.com/home/default.aspx"><img alt="CITIUS Oncology logo." height="39" width="214" src="/images/footer-logo-oncology.png"/></a></div><div class="right"><a class="brand-logo" href="/"><img alt="CITIUS Pharmaceuticals, Inc. Logo." height="45" width="220" src="/images/footer-logo-product.png"/></a></div></div><div class="row"><div class="col-12 text-col"><p>LYMPHIR is a trademark of Citius Oncology, Inc.<!-- --> <!-- -->©2025 Citius Oncology, Inc. All rights reserved.</p><p>11/25 PM-LY-00055</p></div></div></div></div></div></div></footer><style>[data-theme='light-bg'] {--background-color: #ffffff;--color: #595959;--heading-color: #000000;--active-color: #1E5776;--accent-bg-color: #cccccc;--hover-background-color: #42748E;--link-color: #0e8642;--hover-color: #000000;--border-color: #000000;--anchor-bar-bg-color: #F4F7FA;--anchor-bar-dropdown-bg-color: #F4F7FA;--anchor-bar-link-color: #1E5776;--anchor-bar-accent-link-color: #1E5776;--btn-primary-color: #ffffff;--btn-primary-bg-color: #1E5776;--btn-primary-hover-color: #ffffff;--btn-primary-hover-bg-color: #42748E;--btn-primary-disabled-bg-color: #1E5776;--btn-secondary-color: #1E5776;--btn-secondary-bg-color: #FFFFFF;--btn-secondary-border-color: #1E5776;--btn-secondary-hover-color: #FFFFFF;--btn-secondary-hover-bg-color: #1E5776;--btn-secondary-disabled-bg-color: #FFFFFF;--btn-tertiary-color: #1E5776;--btn-tertiary-bg-color: none;--btn-tertiary-hover-color: #42748E;--btn-tertiary-hover-bg-color: none;--btn-tertiary-disabled-bg-color: none;--btn-quaternary-color: #66C125;--btn-quaternary-bg-color: transparent;--btn-quaternary-border-color: #66C125;}[data-theme='dark-bg'] {--background-color: #32566C;--color: #ffffff;--heading-color: #ffffff;--active-color: #d3d3d3;--hover-background-color: #ffffff;--hover-color: #555555;--border-color: #ffffff;--btn-primary-color: #555555;--btn-primary-bg-color: #ffffff;--btn-primary-border-color: #ffffff;--btn-primary-hover-color: #ffffff;--btn-primary-hover-bg-color: #555555;--btn-primary-hover-border-color: #ffffff;--btn-secondary-color: #555555;--btn-secondary-bg-color: #ffffff;--btn-secondary-border-color: #ffffff;--btn-secondary-hover-color: #ffffff;--btn-secondary-hover-bg-color: #555555;--btn-secondary-hover-border-color: #ffffff;--btn-quaternary-color: #66C125;--btn-quaternary-bg-color: transparent;--btn-quaternary-border-color: #66C125;}[data-theme='light-blue-bg'] {--background-color: #F4F7FA;--color: #000000;--heading-color: #000000;--active-color: #66C125;--hover-background-color: #ffffff;--hover-color: #555555;--border-color: #ffffff;--btn-primary-color: #ffffff;--btn-primary-bg-color: #1E5776;--btn-primary-hover-color: #ffffff;--btn-primary-hover-bg-color: #42748E;--btn-primary-hover-border-color: #ffffff;--btn-secondary-color: #555555;--btn-secondary-bg-color: #ffffff;--btn-secondary-border-color: #ffffff;--btn-secondary-hover-color: #ffffff;--btn-secondary-hover-bg-color: #555555;--btn-secondary-hover-border-color: #ffffff;}[data-theme='light-green-bg'] {--background-color: rgba(117, 187, 67, 0.1);--color: #000000;--heading-color: #000000;--active-color: #66C125;--hover-background-color: #ffffff;--hover-color: #555555;--border-color: #ffffff;--btn-primary-color: #555555;--btn-primary-bg-color: #ffffff;--btn-primary-border-color: #ffffff;--btn-primary-hover-color: #ffffff;--btn-primary-hover-bg-color: #555555;--btn-primary-hover-border-color: #ffffff;--btn-secondary-color: #555555;--btn-secondary-bg-color: #ffffff;--btn-secondary-border-color: #ffffff;--btn-secondary-hover-color: #ffffff;--btn-secondary-hover-bg-color: #555555;--btn-secondary-hover-border-color: #ffffff;}</style></div></div>
1<script id="__NEXT_DATA__" type="application/json">{"props":{"pageProps":{"page":{"data":{"_schema":"DefaultPageBuilderTemplate","title":"About CTCL","theme":null,"overrides":{"main_custom_class_names":null},"seo":{"title":null,"description":null,"og_title":null,"og_description":null,"og_image":null,"schema":null},"content_blocks":[{"_id":"Hero/Hero","content_html":"\u003ch1\u003e\u003cspan class=\"accent-color\"\u003e\u003cstrong\u003eCTCL IS AN INCURABLE COMPLEX CANCER\u003c/strong\u003e\u003c/span\u003e\u003cstrong\u003e WITH NO SINGLE DEFINITIVE TREATMENT PATHWAY\u003c/strong\u003e\u003c/h1\u003e","custom_class_names":"","breadcrumb":true,"image":null,"image_alt":null,"image_width":0,"image_height":0,"cms_bind_prefix":"content_blocks[0]"},{"_id":"Factoid/Factoid","version":1,"leftside":false,"short_style":true,"content_html":"\u003cp\u003eThere is no universally defined treatment pathway for CTCL. Patients with advanced or refractory disease have limited durable and tolerable options, and many aspects of treatment need to be considered when choosing a course of therapy\u003csup\u003e1,2\u003c/sup\u003e\u003c/p\u003e","optional_content_html":"","custom_class_names":"","cms_bind_prefix":"content_blocks[1]"},{"_id":"FullBleed/FullBleed","editor_label":"Advanced diseases and pruritus...","child_container_width":"container","theme":"light-bg","background":{"image":"","color":null},"custom_class_names":"","visibility":"","content_blocks":[{"_id":"Spacer/Spacer","mobile_height":20,"height":45,"custom_class_names":"","cms_bind_prefix":"content_blocks[2].content_blocks[0]"},{"_id":"RichText/RichText","content_html":"\u003ch2\u003eAdvanced disease and pruritus can heavily impact quality of life in patients\u003c/h2\u003e\u003cul\u003e\u003cli\u003e\u003cp\u003ePruritus is a common and troublesome symptom in CTCL\u003csup\u003e3\u003c/sup\u003e\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eItching can be very hard to manage in patients with CTCL. A worsening of pruritus is often associated with disease progression. The pathogenesis has not yet been fully elucidated\u003csup\u003e4\u003c/sup\u003e\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eSymptoms of pruritus can be present in a large majority (nearly 90%) of patients with CTCL, and may be associated with decreased quality of life for patients. Patients should be evaluated for pruritus at each visit\u003csup\u003e1\u003c/sup\u003e\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eQuality of life worsens for patients with CTCL as the disease advances. Patients may experience itching and pain, as well as poor sleep, depression, and anxiety\u003csup\u003e5\u003c/sup\u003e\u003c/p\u003e\u003c/li\u003e\u003c/ul\u003e","container_width":"container","custom_class_names":"","text_color":null,"heading_text_color":null,"cms_bind_prefix":"content_blocks[2].content_blocks[1]"},{"_id":"Spacer/Spacer","mobile_height":45,"height":60,"custom_class_names":"","cms_bind_prefix":"content_blocks[2].content_blocks[2]"}],"cms_bind_prefix":"content_blocks[2]"},{"_id":"References/References","custom_class_names":"","version":1,"no_line":true,"reference_items":[{"_id":"References/Reference_items","content_html":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u003csup\u003e®\u003c/sup\u003e) for primary cutaneous lymphomas V.3.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed November 13, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.","cms_bind_prefix":"content_blocks[3].reference_items[0]"},{"_id":"References/Reference_items","content_html":"Shimshak S, Sokumbi O, Isaq N, Goyal A, Comfere N. A practical guide to the diagnosis, evaluation, and treatment of cutaneous T-Cell lymphoma. \u003cem\u003eDermatol Clin\u003c/em\u003e. 2023;41(1):209-229. doi:10.1016/j.det.2022.07.019","cms_bind_prefix":"content_blocks[3].reference_items[1]"},{"_id":"References/Reference_items","content_html":"Wright A, Wijeratne A, Hung T, et al. Prevalence and severity of pruritus and quality of life in patients with cutaneous T-cell lymphoma. \u003cem\u003eJ Pain Symptom Manage.\u003c/em\u003e 2013;45(1):114-119. doi:10.1016/j.jpainsymman.2012.01.012","cms_bind_prefix":"content_blocks[3].reference_items[2]"},{"_id":"References/Reference_items","content_html":"Serrano L, Martinez-Escala ME, Zhou XA, Guitart J. Prur
1itus in Cutaneous T-Cell Lymphoma and Its Management. \u003cem\u003eDermatol Clin.\u003c/em\u003e 2018;36:245â58. doi:10.1016/j.det.2018.02.011","cms_bind_prefix":"content_blocks[3].reference_items[3]"},{"_id":"References/Reference_items","content_html":"Scarisbrick JJ, Bagot M, Ortiz-Romero PL. The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T-cell lymphoma. \u003cem\u003eBr J Haematol.\u003c/em\u003e 2021;192(4):683-696. doi:10.1111/bjh.17117","cms_bind_prefix":"content_blocks[3].reference_items[4]"}],"cms_bind_prefix":"content_blocks[3]"},{"_id":"Spacer/Spacer","mobile_height":50,"height":60,"custom_class_names":"","cms_bind_prefix":"content_blocks[4]"},{"_id":"NextSection/NextSection","custom_class_names":"","title":"NEXT: Learn more about LYMPHIR","links":[{"link_label":"View mechanism of action","link_url":"/lymphir-moa/how-lymphir-works","cms_bind_prefix":"content_blocks[5].links[0]"},{"link_label":"View phase III trial results","link_url":"/efficacy","cms_bind_prefix":"content_blocks[5].links[1]"},{"link_label":"See safety information","link_url":"/safety","cms_bind_prefix":"content_blocks[5].links[2]"}],"cms_bind_prefix":"content_blocks[5]"}]},"slug":"about-ctcl","contentHtml":""}},"__N_SSG":true},"page":"/[...slug]","query":{"slug":["about-ctcl"]},"buildId":"e2ec-LxESpgki9ZsMI16Z","isFallback":false,"gsp":true,"scriptLoader":[]}</script>
1</body></html>
Line numbers count LF bytes from the start of the resource, as the search results do. Vendor segments are library code the classifier recognised; they are stored but not indexed. Bytes are shown as Latin1 characters, one per byte.